Tejaswi Mudigonda

1.1k citations
12 papers · 285 indexed · h-index 8

Tejaswi Mudigonda

11 papers receiving 283 citations

Peers

Tejaswi Mudigonda
Comparison fields: 5 of 69
  • Dermatology 135
  • Immunology 91
  • Oncology 109
  • Epidemiology 123
  • Immunology and Allergy 9
Replace Rosa Fernández‐Torres with:
Rosa Fernández‐Torres Spain
Gaetano Licata Italy
Chrysovalantis Korfitis Greece
Katherine Armour Australia
MARCIA SHAW United Kingdom
Anne-Karine Lapointe Switzerland
Federica Vecchio Italy
Cynthia Marie Carver DeKlotz United States
G. Solano‐López Spain
Amanda Rosenthal United States
Tejaswi Mudigonda relative to Rosa Fernández‐Torres Spain Rosa Fernández‐Torres's profile →
Citations per field
00.5×2.6×
Rosa Fernández‐Torres · 1×
Citations per year

Countries citing papers authored by Tejaswi Mudigonda

Since Specialization
Citations

This map shows the geographic impact of Tejaswi Mudigonda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tejaswi Mudigonda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tejaswi Mudigonda more than expected).

Fields of papers citing papers by Tejaswi Mudigonda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tejaswi Mudigonda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tejaswi Mudigonda. The network helps show where Tejaswi Mudigonda may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Tejaswi Mudigonda, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Tejaswi Mudigonda Line = papers co-authored together Tejaswi Mudigonda links everyone, so they are left out of the graph.

All Works

12 of 12 papers shown
#Work
1 20206
2 20192
3
Horrendous, Treatment-resistant Pediatric Atopic Dermatitis Solved With a Change in Vehicle.
20160
4 201520
5 20154
6 201210
7 201253
8
Therapeutic modalities for localized psoriasis: 308-nm UVB excimer laser versus nontargeted phototherapy.
20129
9 201253
10 201127
11 201088
12 201013

About Tejaswi Mudigonda

Tejaswi Mudigonda is a scholar working on Dermatology, Oncology and Immunology, having authored 12 papers that have together received 285 indexed citations. Recurring topics across this work include Psoriasis: Treatment and Pathogenesis (4 papers), Cutaneous Melanoma Detection and Management (3 papers), Nail Diseases and Treatments (2 papers), Skin Protection and Aging (2 papers), Nonmelanoma Skin Cancer Studies (2 papers), Cancer Immunotherapy and Biomarkers (2 papers), Melanoma and MAPK Pathways (1 paper) and Food Allergy and Anaphylaxis Research (1 paper). The work is most often cited by research in Dermatology (135 citations), Immunology (91 citations) and Oncology (109 citations). Tejaswi Mudigonda has collaborated with scholars based in United States, Germany and United Kingdom. Frequent co-authors include Steven R. Feldman, Daniel J. Pearce, Brad A. Yentzer, Phillip M. Williford, Tushar S. Dabade, Cameron West, Ashley Feneran, Jenna L. OʼNeill, Laura F. Sandoval and Douglas B. Johnson.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026